AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its price target cut by equities research analysts at Morgan Stanley from $26.00 to $22.00 in a research report issued on Friday. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 56.81% from the stock’s previous close.

A number of other equities research analysts have also recently commented on AMAG. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Citigroup Inc. lowered their target price on AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a research note on Friday, July 7th. Deutsche Bank AG set a $24.00 target price on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, July 7th. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Tuesday, July 11th. Finally, Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $25.50.

AMAG Pharmaceuticals (AMAG) traded up $1.23 on Friday, reaching $14.03. 1,815,983 shares of the company’s stock were exchanged, compared to its average volume of 1,069,796. The company has a current ratio of 1.59, a quick ratio of 1.41 and a debt-to-equity ratio of 0.94. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. The firm had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. The business’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.45 EPS. analysts expect that AMAG Pharmaceuticals will post -1.26 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Morgan Stanley Lowers AMAG Pharmaceuticals, Inc. (AMAG) Price Target to $22.00” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/morgan-stanley-lowers-amag-pharmaceuticals-inc-amag-price-target-to-22-00/1681413.html.

A number of institutional investors have recently made changes to their positions in AMAG. State of Alaska Department of Revenue raised its stake in AMAG Pharmaceuticals by 81.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 3,081 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in AMAG Pharmaceuticals by 6.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after acquiring an additional 510 shares during the period. Aperio Group LLC bought a new stake in AMAG Pharmaceuticals in the 3rd quarter valued at about $198,000. Sei Investments Co. raised its stake in AMAG Pharmaceuticals by 29.5% in the 2nd quarter. Sei Investments Co. now owns 10,799 shares of the specialty pharmaceutical company’s stock valued at $199,000 after acquiring an additional 2,457 shares during the period. Finally, Karp Capital Management Corp bought a new stake in AMAG Pharmaceuticals in the 1st quarter valued at about $232,000.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.